Brokers Offer Predictions for FDMT Q1 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of 4D Molecular Therapeutics in a research report issued to clients and investors on Wednesday, November 12th. HC Wainwright analyst M. Caufield anticipates that the company will earn ($1.05) per share for the quarter. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.05) EPS and Q4 2026 earnings at ($1.05) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Monday, November 10th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.40 million.

Several other analysts have also recently commented on FDMT. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, October 8th. Chardan Capital boosted their target price on shares of 4D Molecular Therapeutics from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday. Morgan Stanley raised shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research note on Friday, November 7th. Leerink Partners restated an “outperform” rating and issued a $17.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, October 31st. Finally, Roth Capital dropped their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $28.70.

4D Molecular Therapeutics Stock Performance

FDMT traded down $0.30 during trading on Thursday, reaching $10.67. The company’s stock had a trading volume of 211,326 shares, compared to its average volume of 857,773. The company’s fifty day moving average price is $9.18 and its 200-day moving average price is $6.18. 4D Molecular Therapeutics has a 52-week low of $2.23 and a 52-week high of $12.34. The company has a market capitalization of $498.50 million, a price-to-earnings ratio of -2.83 and a beta of 2.96.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC lifted its holdings in 4D Molecular Therapeutics by 117.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after buying an additional 2,674 shares in the last quarter. Abich Financial Wealth Management LLC bought a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at about $80,000. Inscription Capital LLC bought a new position in 4D Molecular Therapeutics during the 3rd quarter worth $94,000. Impact Partnership Wealth LLC bought a new stake in 4D Molecular Therapeutics in the 3rd quarter valued at about $96,000. Finally, Quadrature Capital Ltd acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at approximately $42,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Insider Buying and Selling at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $12.00, for a total value of $32,136.00. Following the completion of the sale, the insider owned 3,594 shares in the company, valued at $43,128. The trade was a 42.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders sold 9,128 shares of company stock worth $92,100. Corporate insiders own 9.60% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.